research use only

Taletrectinib (DS-6051b) ROS1 inhibitor

Cat.No.S8901

Taletretinib (DS-6051b, AB-106) is a new-generation selective ROS1/NTRK inhibitor, with ic50 values of 0.207 nM, 0.622 nM, 2.28 nM, and 0.980 nM for ROS1, NTRK1, NTRK2, and NTRK3, respectively.
Taletrectinib (DS-6051b) ROS1 inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 551.61

Quality Control

Batch: S890101 DMSO]50 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.98%
99.98

Chemical Information, Storage & Stability

Molecular Weight 551.61 Formula

C29H34FN5O5

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1505515-69-4 -- Storage of Stock Solutions

Synonyms AB-106 Smiles CC(COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)NC(C)C4=CC(=CC=C4)F)N.C(CCC(=O)O)CC(=O)O

Solubility

In vitro
Batch:

DMSO : 50 mg/mL (90.64 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
ROS1 [1]
(Cell-free assay)
0.207 nM
TrkA [1]
(Cell-free assay)
0.622 nM
TrkC [1]
(Cell-free assay)
0.980 nM
TrkB [1]
(Cell-free assay)
2.28 nM
In vitro

Taletrectinib (DS-6051b) inhibited the growth of the CD74-ROS1 overexpressed Ba/F3 cells and the ROS1 fusion-positive HCC78 cancer cell line. It potently inhibited autophosphorylation of ROS1 in CD74-ROS1–expressed Ba/F3 cells and the SLC34A2-ROS1 harboring HCC78 cells at approximately single-digit to double-digit nanomolar concentration.[1]

In vivo

In vivo experiments using the KM12-bearing mouse xenograft model shows that Taletrectinib (DS-6051b) induced tumor shrinkage at a ≥50 mg/kg or higher treatment dose without significant body weight loss.[1]

References

Applications

Methods Biomarkers Images PMID
Western blot pROS1 / ROS1 / pSHP-2 / SHP-2 / pMEK1 / MEK1 / pERK / ERK / pAKT / AKT / Actin S8901-WB-1 31399568
Growth inhibition assay Tumor Volume Cell viability S8901-Growh-inhibition-assay-2 31399568
CT&MRI Tumor Volume S8901-CT-MRI-1 29805770

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04919811 Recruiting
Non Small Cell Lung Cancer
AnHeart Therapeutics Inc.
September 1 2021 Phase 2
NCT05357820 Completed
Solid Tumor
AnHeart Therapeutics Inc.
July 19 2021 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.